Literature DB >> 17396142

Dense deposit disease is not a membranoproliferative glomerulonephritis.

Patrick D Walker1, Franco Ferrario, Kensuke Joh, Stephen M Bonsib.   

Abstract

Dense deposit disease (first reported in 1962) was classified as subtype II of membranoproliferative glomerulonephritis in the early 1970s. Over the last 30 years, marked differences in etiology and pathogenesis between type I membranoproliferative glomerulonephritis and dense deposit disease have become apparent. The sporadic observation that dense deposit disease can be seen with markedly different light microscopy appearances prompted this study. The goal was to examine a large number of renal biopsies from around the world to characterize the histopathologic features of dense deposit disease. Eighty-one cases of dense deposit disease were received from centers across North America, Europe and Japan. Biopsy reports, light microscopy materials and electron photomicrographs were reviewed and histopathologic features scored. Sixty-nine cases were acceptable for review. Five patterns were seen: (1) membranoproliferative n=17; (2) mesangial proliferative n=30; (3) crescentic n=12; (4) acute proliferative and exudative n=8 and (5) unclassified n=2. The age range was 3-67 years, with 74% in the range of 3-20 years; 15% 21-30 years and 11% over 30 years. Males accounted for 54% and females 46%. All patients with either crescentic dense deposit disease or acute proliferative dense deposit disease were between the ages of 3 and 18 years. The essential diagnostic feature of dense deposit disease is not the membranoproliferative pattern but the presence of electron dense transformation of the glomerular basement membranes. Based upon this study and the extensive data developed over the past 30 years, dense deposit disease is clinically distinct from membranoproliferative glomerulonephritis and is morphologically heterogeneous with only a minority of cases having a membranoproliferative pattern. Therefore, dense deposit disease should no longer be regarded as a subtype of membranoproliferative glomerulonephritis.

Entities:  

Mesh:

Year:  2007        PMID: 17396142     DOI: 10.1038/modpathol.3800773

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  39 in total

Review 1.  C3 glomerulopathy: a new classification.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi; Laure-Hélène Noël; H Terence Cook; Matthew C Pickering
Journal:  Nat Rev Nephrol       Date:  2010-07-06       Impact factor: 28.314

Review 2.  Dense Deposit Disease Mimicking a Renal Small Vessel Vasculitis.

Authors:  Lavleen Singh; Geetika Singh; Swati Bhardwaj; Aditi Sinha; Arvind Bagga; Amit Dinda
Journal:  J Am Soc Nephrol       Date:  2015-09-11       Impact factor: 10.121

3.  American Society of Nephrology clinical pathological conference.

Authors:  Kevin E Meyers; Helen Liapis; Mohamed G Atta
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 8.237

4.  Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.

Authors:  Jennifer Laskowski; Brandon Renner; Moglie Le Quintrec; Sarah Panzer; Jonathan P Hannan; Danica Ljubanovic; Marieta M Ruseva; Dorin-Bogdan Borza; Alexandra H Antonioli; Matthew C Pickering; V Michael Holers; Joshua M Thurman
Journal:  Kidney Int       Date:  2016-05-07       Impact factor: 10.612

5.  Defining the complement biomarker profile of C3 glomerulopathy.

Authors:  Yuzhou Zhang; Carla M Nester; Bertha Martin; Mikkel-Ole Skjoedt; Nicole C Meyer; Dingwu Shao; Nicolò Borsa; Yaseelan Palarasah; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-23       Impact factor: 8.237

Review 6.  Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.

Authors:  Andrew S Bomback; Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

7.  Clinical features and outcomes of 98 children and adults with dense deposit disease.

Authors:  Der-Fa Lu; Mikyung Moon; Lynne D Lanning; Ann Marie McCarthy; Richard J H Smith
Journal:  Pediatr Nephrol       Date:  2011-11-22       Impact factor: 3.714

Review 8.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

9.  Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.

Authors:  Rupali S Avasare; Pietro A Canetta; Andrew S Bomback; Maddalena Marasa; Yasar Caliskan; Yasemin Ozluk; Yifu Li; Ali G Gharavi; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-11       Impact factor: 8.237

Review 10.  Treatment options for C3 glomerulopathy.

Authors:  Carla M Nester; Richard J Smith
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-03       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.